Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002733 · ClinicalTrials.gov registry record · Phase 2
Biological Therapy in Treating Patients With Metastatic Cancer
A Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00002733 is a Phase 2 study that has completed, run by Hoag Memorial Hospital Presbyterian. The registered enrollment target is 30 participants.
The verdict
NCT00002733, a Phase 2 study, has completed, sponsored by Hoag Memorial Hospital Presbyterian.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, in treating patients with metastatic cancer.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL therapeutic tumor infiltrating lymphocytes
- DRUG cimetidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1996-01 |
| Est. Completion | 2000-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002733
The ClinicalTrials.gov registry entry for NCT00002733 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoag Memorial Hospital Presbyterian, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which aldesleukin is the first listed.
NCT00002733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002733 about?
NCT00002733 is a clinical study titled "Biological Therapy in Treating Patients With Metastatic Cancer". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies, including interferon alfa, interleukin-2, and tumor infiltrating lymphocytes, may kill more cancer cells. PURPOSE: Phase II trial ...
What is the current status of trial NCT00002733?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1996-01. Estimated completion is 2000-01.
What interventions are being tested in trial NCT00002733?
The interventions under investigation include: aldesleukin (BIOLOGICAL), recombinant interferon alfa (BIOLOGICAL), therapeutic tumor infiltrating lymphocytes (BIOLOGICAL), cimetidine (DRUG).
Who is sponsoring clinical trial NCT00002733?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.